Analyst reactions to Altimmune’s Phase IIb data for dual GLP-1/GIP receptor agonist pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) were mixed as the candidate showed ability to resolve disease, although without improving fibrosis, but investors were decidedly unimpressed, sending the company’s stock price lower for two days in a row.
Key Takeaways
- Altimmune demonstrated an ability to resolve MASH but not to significantly improve fibrosis in a Phase IIb study of its MASH candidate pemvidutide.
Altimmune executive stressed during a conference call accompanying its June 26 data release that pemvidutide also yielded weight loss up...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?